Cannvas MedTech (CSE:MTEC), a leading business technology company in the cannabis space, is pleased to announce that it has signed a partnership agreement with the Business of Cannabis, an online B2B cannabis media platform for news, analysis and insights into the business of Canada’s cannabis sector, for the creation of a series of data projects aimed at delivering insights to the industry.

“The team at Cannvas are about to launch an online platform for cannabis content, education and understanding of the wide-ranging benefits of cannabis,” said Jay Rosenthal, Co-Founder and President, Business of Cannabis. “We look forward to leveraging this data to enhance and enrich the content and insights that we provide to our ever-growing audience across Canada and beyond.”


“As a regular reader of Business of Cannabis, I have always been impressed at the quality and breadth of content they produce; it is tailored to our industry and comes from real industry insiders,” said Shawn Moniz, Chief Executive Officer of Cannvas. “As we continue to roll out our innovative Canvass.me platform, we will work closely with the team at Business of Cannabis to develop meaningful content to engage a broader audience on an individually tailored basis. We see great potential in this partnership.”

With more than 260,000 Canadians already having legal, medical access to cannabis, and adult-use recreational cannabis arriving on October 17, 2018, the opportunity exists for Cannvas and Business of Cannabis to develop and broadcast valuable content and data for the sector and beyond.

About Business of Cannabis

Business of Cannabis is the authoritative platform for news, analysis and insights into the business of Canada’s cannabis sector. We believe that expert information empowers professionals to best leverage opportunities and navigate obstacles. We produce original multiplatform content and cross sector coverage to serve those working in and alongside the industry. Find out more: businessofcannabis.ca.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: www.cannvasmedtech.com; Media Inquiries, media@cannvasmedtech.com; Investor Relations, ir@cannvasmedtech.com, 1-800-489-0116

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less